Lek Pharmaceuticals DD

General

Total Cases26

Active Cases2

Patents99

CourtsD. Delaware D. New Jersey N.D. California

TypeOperating Company

Elite Ratings

--

lek-pharmaceuticals

Ratings

Experience

Grade

Trend

DCT

L1

E

PTAB

L2

B

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
12/23/24	Amgen Inc v. Sandoz Inc 1:23-CV-02406 ( D. NJ )	LETTER ORDER, Granting a 3-week extension to the current deadline to move for a protective order. The new deadline will be January 10, 2025; the current deadline for the parties in this matter to destroy/archive confidential discovery material as required by the Discovery Confidentiality Order (DCO) is extended to January 27, 2025. Signed by Magistrate Judge Elizabeth A. Pascal on 12/23/2024. (js) (Entered: 12/23/2024) LETTER ORDER, Granting a 3-week extension to the current deadline to move for a protective order. The new deadline will be January 10, 2025; the current deadline for the parties in this matter to destroy/archive confidential discovery material as required by the Discovery Confidentiality Order (DCO) is extended to January 27, 2025. Signed by Magistrate Judge Elizabeth A. Pascal on 12/23/2024. (js) (Entered: 12/23/2024)
12/20/24	Amgen Inc v. Sandoz Inc 1:23-CV-02406 ( D. NJ )	Letter from E. Abraham to Judge Pascal. (ABRAHAM, ERIC) (Entered: 12/20/2024)
12/18/24	Astellas Pharma Inc v. Sandoz Inc 1:20-CV-01589 ( D. DE )	Pro Hac Vice Attorney Michael DelRossi for Astellas Ireland Co., Ltd.,Michael DelRossi for Astellas Pharma Global Development, Inc.,Michael DelRossi for Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 12/18/2024)
12/16/24	Astellas Pharma Inc v. Sandoz Inc 1:20-CV-01589 ( D. DE )	ORDER: The briefing schedule ordered, D.I. [631] , is reinstated, but limited to the issues of validity under 35 U.S.C. § 112. Within 30 days of the date of this Order, the parties will simultaneously file briefing addressing any pertinent changes in law that have occurred since the parties' post-trial briefing. The parties may file a response any time before the scheduled hearing. The parties shall inform the Court of their availability for oral argument in Wilmington, the weeks of January 26, 2025, and February 2, 2025. The parties shall meet, confer, and propose a schedule for parallel resolution and/or consolidation of this case with lead cases 21-cv-664, 23-cv-819, 24-cv-819, 24-cv-1068, 24-cv-1069, 24-cv-939, and 24-cv-940. During their meeting, the parties should also address whether the pending ANDA actions regarding Ascent Pharmaceuticals and MSM (Docket Numbers 23-cv-486, 23-cv-689, and 24-cv-1084) involving the same patents should be scheduled for resolution on the same timeline (if not at the same trial). SEE ORDER FOR FURTHER DETAILS. Signed by Judge Joseph F. Bataillon on 12/16/2024. (jfm) (Entered: 12/16/2024) ORDER: The briefing schedule ordered, D.I. [631] , is reinstated, but limited to the issues of validity under 35 U.S.C. § 112. Within 30 days of the date of this Order, the parties will simultaneously file briefing addressing any pertinent changes in law that have occurred since the parties' post-trial briefing. The parties may file a response any time before the scheduled hearing. The parties shall inform the Court of their availability for oral argument in Wilmington, the weeks of January 26, 2025, and February 2, 2025. The parties shall meet, confer, and propose a schedule for parallel resolution and/or consolidation of this case with lead cases 21-cv-664, 23-cv-819, 24-cv-819, 24-cv-1068, 24-cv-1069, 24-cv-939, and 24-cv-940. During their meeting, the parties should also address whether the pending ANDA actions regarding Ascent Pharmaceuticals and MSM (Docket Numbers 23-cv-486, 23-cv-689, and 24-cv-1084) involving the same patents should be scheduled for resolution on the same timeline (if not at the same trial). SEE ORDER FOR FURTHER DETAILS. Signed by Judge Joseph F. Bataillon on 12/16/2024. (jfm) (Entered: 12/16/2024)
12/12/24	Amgen Inc v. Sandoz Inc 1:23-CV-02406 ( D. NJ )	LETTER ORDER Granting Sandoz Inc's request for a 9-day extension of the current to move for a protective order from discovery, to December 20, 2024; Granting Amgen and Sandoz Inc's request for a further extension to destroy/archive confidential discovery material by 10-days, to January 3, 2025. Signed by Magistrate Judge Elizabeth A. Pascal on 12/12/2024. (sms2) (Entered: 12/12/2024)
12/11/24	Amgen Inc v. Sandoz Inc 1:23-CV-02406 ( D. NJ )	Letter from E. Abraham to Judge Pascal. (ABRAHAM, ERIC) (Entered: 12/11/2024)
12/06/24	Astellas Pharma Inc v. Sandoz Inc 1:20-CV-01589 ( D. DE )	SO ORDERED, D.I. 650 MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. Signed by Judge Joseph F. Bataillon on 12/6/24. (AEV) (Entered: 12/06/2024)
12/04/24	Astellas Pharma Inc v. Sandoz Inc 1:20-CV-01589 ( D. DE )	Pro Hac Vice Fee - Credit Card Payment received for Michael DelRossi. ( re [650] MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi )( Payment of $ 50, receipt number ADEDC-4562585).(Silver, Daniel) (Entered: 12/04/2024)
12/04/24	Astellas Pharma Inc v. Sandoz Inc 1:20-CV-01589 ( D. DE )	MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Attachments: # [1] Certification for Michael DelRossi)(Silver, Daniel) (Entered: 12/04/2024)
12/03/24	Amgen Inc v. Sandoz Inc 1:23-CV-02406 ( D. NJ )	NOTICE of Appearance by KEITH J. MILLER on behalf of NOVARTIS AG (MILLER, KEITH) (Entered: 12/03/2024)